Biosimilars accessible in the market for the treatment of cancer
Copyright © 2021 Elsevier B.V. All rights reserved..
Biosimilars are the biological product clinically identical to a biologic reference standard regarding their strength, purity, and safety. A large segment of biosimilars has been developed for the treatment of cancer. This review aims to discuss various facets of biosimilars and explicates on biosimilars accessible in the market for cancer clinical intervention. It also illustrates the outcomes of recent clinical trial studies concerning biosimilars. Further, it also crosstalk the safety profiles, regulatory approval requirements, and allied challenges therein. The work will be of significant interest to researchers working in the field of biologics and biosimilars.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:336 |
|---|---|
| Enthalten in: |
Journal of controlled release : official journal of the Controlled Release Society - 336(2021) vom: 10. Aug., Seite 112-129 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ditani, Aayushi S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biologics |
|---|
| Anmerkungen: |
Date Completed 28.10.2021 Date Revised 28.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jconrel.2021.06.014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326740252 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326740252 | ||
| 003 | DE-627 | ||
| 005 | 20231225195241.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jconrel.2021.06.014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1089.xml |
| 035 | |a (DE-627)NLM326740252 | ||
| 035 | |a (NLM)34126171 | ||
| 035 | |a (PII)S0168-3659(21)00301-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ditani, Aayushi S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Biosimilars accessible in the market for the treatment of cancer |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.10.2021 | ||
| 500 | |a Date Revised 28.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier B.V. All rights reserved. | ||
| 520 | |a Biosimilars are the biological product clinically identical to a biologic reference standard regarding their strength, purity, and safety. A large segment of biosimilars has been developed for the treatment of cancer. This review aims to discuss various facets of biosimilars and explicates on biosimilars accessible in the market for cancer clinical intervention. It also illustrates the outcomes of recent clinical trial studies concerning biosimilars. Further, it also crosstalk the safety profiles, regulatory approval requirements, and allied challenges therein. The work will be of significant interest to researchers working in the field of biologics and biosimilars | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Biosimilars | |
| 650 | 4 | |a biologics | |
| 650 | 4 | |a cancers | |
| 650 | 4 | |a clinical trials | |
| 650 | 4 | |a marketed product | |
| 650 | 4 | |a safety | |
| 650 | 7 | |a Biosimilar Pharmaceuticals |2 NLM | |
| 700 | 1 | |a Mallick, Pragyan Paramita |e verfasserin |4 aut | |
| 700 | 1 | |a Anup, Neelima |e verfasserin |4 aut | |
| 700 | 1 | |a Tambe, Vishakha |e verfasserin |4 aut | |
| 700 | 1 | |a Polaka, Suryanarayana |e verfasserin |4 aut | |
| 700 | 1 | |a Sengupta, Pinaki |e verfasserin |4 aut | |
| 700 | 1 | |a Rajpoot, Kuldeep |e verfasserin |4 aut | |
| 700 | 1 | |a Tekade, Rakesh K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of controlled release : official journal of the Controlled Release Society |d 1996 |g 336(2021) vom: 10. Aug., Seite 112-129 |w (DE-627)NLM085820296 |x 1873-4995 |7 nnns |
| 773 | 1 | 8 | |g volume:336 |g year:2021 |g day:10 |g month:08 |g pages:112-129 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jconrel.2021.06.014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 336 |j 2021 |b 10 |c 08 |h 112-129 | ||